hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06384196 id: PID2022-138902OB-I00 briefTitle: Identity-Based Transdiagnostic Therapy for Young People With Anxiety and Depression acronym: IBTTYOUNG overallStatus: NOT_YET_RECRUITING date: 2024-07-02 date: 2025-06-30 date: 2025-11-02 date: 2024-04-25 date: 2024-04-25 name: University of Barcelona class: OTHER name: Badalona Serveis Assistencials name: Nou Barris Mental Health Center briefSummary: Depression and anxiety are the most prevalent mental disorders among both the general population and young adults, and transdiagnostic treatments for these patients are mostly based on cognitive-behavioral therapy (CBT). Based on common (transdiagnostic) principles of treatment (e.g., emotional exposure), these approaches have proliferated and demonstrated their efficacy in comparison to disorder-specific treatments. Although there are a few transdiagnostic approaches for children and adolescents, we could not find anyone targeting young people. For this reason, we propose the Identity-Based Transdiagnostic Therapy (IBTT) as a new treatment modality ideally created to address the challenge of improving the outcomes of psychotherapy for young adults with anxiety and/or depression. The IBTT is a psychological treatment for emotional disorders specifically designed for the youths in terms of their attitudes to treatment (attractiveness, engagement), and highly personalized to their construal of self and others. This project will allow testing the hypothesis that a novel brief psychotherapeutic intervention, IBTT, will be more efficacious in the treatment of the anxiety and/or depression of young adults than the well-established CBT-based Unified Protocol. conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The main study of this project proposal is a multi-center, single-blind, parallel-group randomized clinical trial (RCT) conducted in Catalonia (Spain). primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 138 type: ESTIMATED name: Identity-Based Transdiagnostic Therapy (IBTT) name: Unified Protocol measure: Depression, Anxiety and Stress Scales (DASS-21) measure: Clinical Outcomes in Routine Evaluation-Short Form B (CORE-SFB) measure: Mini International Neuropsychiatric Interview (MINI) measure: Session Rating Scale 3.0 (SRS 3.0) measure: Life Satisfaction Scale (LSS) measure: Self-Concept Clarity Scale (SCCS) measure: Rosenberg Self-Esteem Scale (RSES) measure: Metacognition Self-Assessment Scale (MSAS) measure: Problem definition form measure: Change Interview measure: Consumer Reports Effectiveness Scale (CRES-4) sex: ALL minimumAge: 16 Years maximumAge: 29 Years stdAges: CHILD stdAges: ADULT facility: Badalona Serveis Assistencials city: Badalona zip: 08911 country: Spain name: Irene Alvarez, PhD role: CONTACT email: iatomas@bsa.cat lat: 41.45004 lon: 2.24741 facility: Associació Centre Higiene Mental Nou Barris city: Barcelona zip: 08042 country: Spain name: Giuseppina Rametti, PhD role: CONTACT email: giusi.rametti@csm9b.com lat: 41.38879 lon: 2.15899 hasResults: False
nctId: NCT06384183 id: KS-1000 briefTitle: Kerecis Real World Registry overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-06 date: 2027-06 date: 2024-04-25 date: 2024-04-26 name: Kerecis Ltd. class: INDUSTRY briefSummary: Multi-center, observational (i.e., non-interventional), open-label, real-world Registry on the Use of Kerecis Devices conditions: Wounds conditions: Pressure Ulcer conditions: Diabetic Foot Ulcer conditions: Venous Leg Ulcer conditions: Surgical Wound conditions: Soft Tissue Reinforcement studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: OTHER count: 600 type: ESTIMATED name: Kerecis Fish Skin Graft measure: Fish Skin Graft Device Related failure measure: Fish Skin Graft Device related allergy measure: Target Wound Infection measure: Complete Wound Healing measure: Complete Wound Closure sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384170 id: IRB00442113 briefTitle: Closed Loop Spinal Cord Stimulation for Neuromodulation of Upper Motor Neuron Lesion Spasticity acronym: CLONUS overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2026-01 date: 2026-05 date: 2024-04-25 date: 2024-04-26 name: Johns Hopkins University class: OTHER name: Saluda Medical Pty Ltd briefSummary: Spasticity is characterized by increased muscle tension and is a classic consequence of upper motor neuron (UMN) damage in the central nervous system, such as from stroke or trauma. Clinically, it presents as muscle resistance to passive stretching, along with clasp-knife rigidity, clonus, increased tendon reflexes, and muscle spasms. An imbalance of the descending inhibitory and muscle stretch reflexes is thought to be the cause of spasticity. Post-stroke spasticity is a common condition that occurs in 37.5-45% of cases in the acute stage and 19-57.4% in the subacute stage after a stroke. At 6 months post-stroke, spasticity develops in 42.6-49.5% of cases, and at one year, it affects 35-57.4% of individuals. In patients with cerebral palsy (CP), incidence is almost 80% while in those living with spinal cord injury the number approaches up to 93%. Traumatic brain injury (TBI) patients have a higher prevalence on initial admission to neurorehabilitation but one in three patients will have chronic spasticity. However, the Defense and Veterans Brain Injury Center report a rate of TBIs amongst deployed veterans to be around 11-23% mostly from blast and explosive trauma.
There have been studies as early as the 1980s exploring the efficacy of SCS for spasticity control, however, the credibility of many of these studies is constrained due to an incomplete comprehension of spasticity's underlying mechanisms, outdated research methods, and early limitations in implantable device technology. Intrathecal pumps for baclofen have remained as the mainstay for refractory spasticity, however, it comes with associated risks such as chemical dependence leading to acute baclofen withdrawal and requiring frequent refill requirement. Most importantly, it does not yield functional improvement of muscle activity, just suppression of spasticity. Botox is also routinely used but due to heterogeneity in muscle involvement as well as variability in provider skill, results may be inconsistent and short-lasting, requiring frequent clinic visits for repeat injections to the affected muscle groups. SCS may be able to address that gap in spasticity management. conditions: Chronic Pain conditions: Spasticity as Sequela of Stroke conditions: Upper Motor Neuron Lesion studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 12 type: ESTIMATED name: Spinal Cord Stimulation- Closed loop measure: Pain as assessed by Visual Analog Score measure: Spasticity Reduction as assessed by the Modified Ashworth's Score measure: Short Form 36 Health Survey (SF-36) score measure: Medication Use measure: Health Status as assessed by the EuroQol 5 Dimension 5 Level (EQ-5D-5L) measure: Spinal cord neurophysiological wave morphology measure: Spinal cord neurophysiological Current (mA/mV) measure: Spinal Cord Neurophysiological Characteristic- Conduction Velocity (m/s) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Hospital city: Baltimore state: Maryland zip: 21287 country: United States lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06384157 id: INDV-2000-201 briefTitle: Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-08 date: 2025-09 date: 2024-04-25 date: 2024-04-29 name: Indivior Inc. class: INDUSTRY briefSummary: The purpose of this study is to measure safety and efficacy and to determine dose-response relationship for INDV-2000 in participants with moderate to severe Opioid Use Disorder (OUD) who are new to treatment, have recently initiated or completed short-term medically supervised withdrawal with transmucosal (TM) buprenorphine, and are interested in transitioning to a non opioid treatment. conditions: Opioid Use Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: This is a randomized, double-blind, placebo-controlled study where the investigator, assessor, sponsor and participant are masked. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 300 type: ESTIMATED name: INDV-2000 name: Placebo measure: Proportion (probability) of participants without treatment failure by the end of Week 12 (Day 85). measure: Proportion (probability) of visits with opioid abstinence while participants are on IMP alone. measure: Participant's percentage of visits with opioid abstinence during the whole study follow-up. measure: Incidence, severity and relatedness of adverse events, treatment-emergent adverse events, serious adverse events and events leading to discontinuation and deaths. measure: Opioid Craving Assessment measure: Cmax on Day 1 and Day 15/16 measure: Tmax on Day 1 and Day 15/16 measure: AUC0-24 on Day 1 and Day 15/16 measure: Cavg on Day 1 and Day 15/16 measure: Cmin on Day 1 and Day 15/16 measure: CL/F on Day 1 and Day 15/16 measure: Clinical Opiate Withdrawal Scale (COWS) score sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384144 id: 23QC8155 briefTitle: Machine Learning Miscarriage Management Clinical Decision Support Tool Study acronym: MLMM overallStatus: RECRUITING date: 2023-01-01 date: 2024-06-01 date: 2026-06-01 date: 2024-04-25 date: 2024-04-25 name: Imperial College London class: OTHER briefSummary: Machine learning used to develop an algorithm to determine chance of success with expectant or medical management for an individual patient. Taking into account the following objective measures:
Audit to collate 1000 cases and identify features contributing to an algorithm that can predict outcome of miscarriage management for individualized case management. conditions: Miscarriage in First Trimester studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1000 type: ESTIMATED name: Expectant Management of First Trimester Miscarriage name: Medical Management of First Trimester Miscarriage measure: Machine learning predictive model development for miscarriage management outcomes. measure: Prospective audit to test and validate predictive model sex: FEMALE minimumAge: 16 Years maximumAge: 55 Years stdAges: CHILD stdAges: ADULT facility: Imperial College Heatlhcare NHS Trust status: RECRUITING city: London zip: W12 0HS country: United Kingdom name: Sughashini Murugesu role: CONTACT phone: 07988390772 email: sughashini.murugesu@nhs.net lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06384131 id: ABI-4334-102 id: 2024-511051-18 type: EUDRACT_NUMBER briefTitle: A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection overallStatus: NOT_YET_RECRUITING date: 2024-04-30 date: 2025-04-22 date: 2025-04-22 date: 2024-04-25 date: 2024-04-25 name: Assembly Biosciences class: INDUSTRY briefSummary: This is a randomized, blinded, placebo-controlled, dose-ranging Phase 1b study of the safety, PK, and antiviral activity of ABI-4334 in treatment-naïve or off-treatment chronic Hepatitis B virus (cHBV) subjects that are Hepatitis B e antigen (HBeAg) positive or negative. The study will enroll up to 5 sequential cohorts of 10 subjects each, for a total of up to 50 subjects, randomized 8:2 to receive ABI-4334 or placebo. conditions: Chronic Hepatitis B studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Triple (Participant, Care Provider, Investigator) whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 50 type: ESTIMATED name: ABI-4334 name: Placebo measure: Primary Outcome Measure measure: Maximum Plasma Concentration (Cmax) of ABI-4334 in subjects with cHBV measure: Minimum Plasma Concentration (Cmin) of ABI-4334 in subjects with cHBV measure: Area Under Plasma Concentration-Time Curve (AUC) of ABI-4334 in subjects with cHBV measure: Time to Maximum Plasma Concentration (Tmax) of ABI-4334 in subjects with cHBV measure: Elimination half-life (t1/2) of ABI-4334 in subjects with cHBV measure: To evaluate the changes in HBV DNA (IU/mL or Log IU/mL) in subjects with cHBV measure: Proportion of subjects with HBV DNA < lower limit of quantification (LLOQ) and/or limit of detection (LOD) measure: Mean time elapsed to subjects achieving HBV DNA < LLOQ and/or LOD sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06384118 id: YZUHL20220047 briefTitle: Effects of a Health Intervention on Hypoglycemic Coping : a Pilot Study overallStatus: COMPLETED date: 2023-08-01 date: 2024-01-17 date: 2024-01-17 date: 2024-04-25 date: 2024-04-25 name: Yating Liu class: OTHER briefSummary: From August 2023 to January 2024, 100 patients with type 2 diabetes who met the inclusion and exclusion criteria were selected from the endocrinology department of The purpose of this study was to construct a hypoglycemia coping intervention program for type 2 diabetic patients based on the IMB theory and to investigate the feasibility, acceptability, and initial effects of the program. conditions: Type 2 Diabetes Mellitus conditions: Hypoglycemia conditions: Health Education studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ACTUAL name: Impact of an IMB theory-based health education intervention on hypoglycemic coping in patients with type 2 diabetes: a pilot study measure: The hypoglycemic coping style measure: hypoglycemic fear behavioral measure: Hypoglycemia fear worry measure: Level of health information access behavior measure: Level of health beliefs measure: Level of diabetes knowledge sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ya ting Liu city: Yangzhou state: 未选择 country: China lat: 32.39722 lon: 119.43583 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-08-01 uploadDate: 2024-04-16T10:45 filename: Prot_SAP_000.pdf size: 233766 hasResults: False
nctId: NCT06384105 id: PRDE1 briefTitle: Study of the Patient Radiation Dose During Five Endourological Procedures acronym: PRDE overallStatus: RECRUITING date: 2023-12-19 date: 2024-12-18 date: 2024-12-18 date: 2024-04-25 date: 2024-04-25 name: Universiteit Antwerpen class: OTHER briefSummary: In the medical world more and more procedures are performed with the use of ionizing radiation (x-ray), both diagnostic and therapeutic. The main and most known risk is the development of malignancies as a result of the use of ionizing radiation.
Purpose of this study: To examine the patient radiation dose (PRD) if the frames per second (FPS) are set differently during the five most performed endourological procedures where fluoroscopy is used (insertion/replacement of ureteral stent, (mini-)percutaneous nephrolithotomy (PCNL/PNL), ureterorenoscopy (URS) and extracorporeal shock wave lithotripsy (ESWL/SWL)) and to propose an acceptable PRD for these procedures in a multicentric study. conditions: Radiation Exposure conditions: Urolithiasis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 870 type: ESTIMATED name: frames per second measure: Dose limit measure: Difference in PRD measure: PRD different centres measure: PRD difference complicated cases sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: AZ Klina status: RECRUITING city: Brasschaat state: Antwerp zip: 2930 country: Belgium name: Vincent De Coninck, MD role: CONTACT phone: +32 3 650 50 56 phoneExt: +32 email: vincent.de.coninck@klina.be lat: 51.2912 lon: 4.49182 facility: UZA status: RECRUITING city: Edegem state: Antwerp zip: 2650 country: Belgium name: Stefan De Wachter, MD role: CONTACT phone: +32 3 821 33 68 phoneExt: +32 email: stefan.de.wachter@uza.be lat: 51.15662 lon: 4.44504 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-07-06 uploadDate: 2024-04-22T15:53 filename: ICF_000.pdf size: 735146 hasResults: False
nctId: NCT06384092 id: NB240005-NB-V briefTitle: Process Validation in Dermatology: Assessing Methods for UV Exposure (Artificial Source vs. Sunlight) and Efficacy Evaluation of Anti-Tanning Agents overallStatus: COMPLETED date: 2024-03-07 date: 2024-03-13 date: 2024-03-13 date: 2024-04-25 date: 2024-04-29 name: NovoBliss Research Pvt Ltd class: OTHER briefSummary: The rationale of this study is to establish a robust method for assessing sun protection product efficacy in preventing erythema and tanning. Employing both artificial ultraviolet-A Irradiation and natural direct sunlight exposure, the investigation seeks to provide a reliable methodology, ensuring reproducibility and enabling a direct comparison between these methods. Meticulously determining optimal UV dosages, the study prioritizes inducing skin responses for evaluation while avoiding adverse effects like blistering. The localized validation of UV exposure techniques, tailored to the Indian population, contributes significantly to the field by addressing diverse skin types and environmental conditions. By incorporating both artificial and natural (direct sunlight) UV exposure methods, the study aspires to enhance the safety and effectiveness of future dermatological investigations, benefiting both the scientific community and the broader population. conditions: Skin Pigmentation studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Proof of science/concept primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 6 type: ACTUAL name: Test Sun Protection Cream name: Benchmark Sun Protection Cream measure: Changes in Melanine index using instrumental assessment measure: Change in erythema index using instrumental assessment measure: Change in skin erythema/dryness/wrinkles and oedema using draize scale sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: NovoBliss Research Pvt Ltd city: Gandhinagar state: Gujarat zip: 382421 country: India lat: 23.21667 lon: 72.68333 hasResults: False
nctId: NCT06384079 id: STU00219828 briefTitle: Duration of Ureteral Rest Prior to Ureteral Reconstruction Surgery overallStatus: RECRUITING date: 2024-05 date: 2025-11 date: 2030-11 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: Our objective is to assess the effect of duration of ureteral rest, defined as time from conversion of ureteral stent to percutaneous nephrostomy, on stricture length prior to ureteral reconstruction surgery. conditions: Ureteral Stricture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Antegrade and retrograde pyelogram measure: Ureteral stricture length measured by antegrade or retrograde pyelogram measure: Ureteral Stricture Quality will be graded as either narrowed or obliterated segment. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Northwestern University status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Emily Ji role: CONTACT phone: 312-695-8146 email: emily.ji@nm.org name: Ziho Lee, MD role: PRINCIPAL_INVESTIGATOR lat: 41.85003 lon: -87.65005 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-25 uploadDate: 2024-03-01T13:40 filename: Prot_000.pdf size: 140931 hasResults: False
nctId: NCT06384066 id: STU00219774 briefTitle: Mobile Health Application to Improve Patient Satisfaction After Urethroplasty overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-25 date: 2024-04-25 name: Northwestern University class: OTHER briefSummary: Create a custom urethroplasty mobile application that will guide patients through through the surgical process. conditions: Urethral Stricture studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 80 type: ESTIMATED name: GetWell Mobile Application name: Standard of Care measure: Improve patient satisfaction, education and reported outcomes measure: Change in rate of patient phone calls and messages measure: Rate of emergency department visits sex: ALL minimumAge: 18 Years maximumAge: 89 Years stdAges: ADULT stdAges: OLDER_ADULT typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-04 uploadDate: 2024-03-01T13:15 filename: Prot_000.pdf size: 9077970 hasResults: False
nctId: NCT06384053 id: SAHARA Trial briefTitle: Skin Cancer and Hyperthermia and Radiotherapy acronym: SAHARA overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-07-01 date: 2028-07-01 date: 2024-04-25 date: 2024-04-25 name: Kantonsspital Winterthur KSW class: OTHER name: Luzerner Kantonsspital briefSummary: The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC). conditions: Basal Cell Carcinoma conditions: Squamous Cell Carcinoma Skin conditions: Non-melanoma Skin Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined name: Radiotherapy (RT) measure: Local control measure: Analysis measure: Late toxicities measure: Quality of life assessment sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Kantonsspital Winterthur city: Winterthur state: Kanton Zuerich zip: 8401 country: Switzerland lat: 47.50564 lon: 8.72413 facility: Luzerner Kantonsspital city: Luzern zip: 6000 country: Switzerland name: Winfried Arnold, MD role: CONTACT lat: 47.05048 lon: 8.30635 hasResults: False